• 1. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
• 2. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 3. Fe3O4–Pd Janus nanoparticles with amplified dual-mode hyperthermia and enhanced ROS generation for breast cancer treatment?
  Yanyun Wang,Huijun Ma,Galong Li,Fei Gao,Mingli Peng,Hai Ming Fan Nanoscale Horiz., 2019,4, 1450-1459
• 4. Enantiocontrolled construction of sistodiolynne, an unusual polyketide from the wood-decay fungus Sistrema raduloides
  Chem. Commun., 1997, 767-768
• 5. Exchanged ligands on the surface of a giant cluster: [(MoO3)176(H2O)63(CH3OH)17Hn](32 – n)–
  Chem. Commun., 1998, 1501-1502

Professional Introduction to 4-(Hydroxymethyl)-3-propionylmandelic Acid (CAS No. 1805908-27-3)

4-(Hydroxymethyl)-3-propionylmandelic acid is a specialized organic compound that has garnered significant attention in the field of pharmaceutical chemistry and biochemistry due to its unique structural properties and potential biological activities. With a CAS number of 1805908-27-3, this compound has been the subject of extensive research, particularly in the development of novel therapeutic agents and the exploration of metabolic pathways. This introduction aims to provide a comprehensive overview of the compound, its chemical characteristics, pharmacological significance, and recent advancements in its application.

The molecular structure of 4-(Hydroxymethyl)-3-propionylmandelic acid consists of a mandelic acid backbone modified with a hydroxymethyl group at the fourth carbon position and a propionyl group at the third carbon position. This dual functionality imparts distinct reactivity and binding capabilities, making it a valuable intermediate in synthetic chemistry. The presence of both hydroxymethyl and carboxylic acid groups allows for diverse chemical modifications, enabling the synthesis of more complex molecules with tailored biological properties.

In recent years, 4-(Hydroxymethyl)-3-propionylmandelic acid has been studied for its potential role in modulating various biological pathways. One of the most notable areas of research has been its application in drug discovery and development. The compound's ability to interact with multiple targets has led to investigations into its efficacy as an anti-inflammatory agent, an antioxidant, and even as a potential chemopreventive agent. These studies have been bolstered by computational modeling and high-throughput screening techniques, which have identified promising lead compounds derived from this scaffold.

One of the most intriguing aspects of 4-(Hydroxymethyl)-3-propionylmandelic acid is its role in metabolic pathways related to energy homeostasis and lipid metabolism. Research has suggested that derivatives of this compound may influence key enzymes involved in these processes, offering potential therapeutic benefits for conditions such as obesity and type 2 diabetes. Furthermore, studies have explored its interactions with polyphenolic compounds, indicating that it may enhance the bioavailability and therapeutic effects of these natural products through synergistic mechanisms.

The synthesis of 4-(Hydroxymethyl)-3-propionylmandelic acid presents both challenges and opportunities for chemists. Traditional synthetic routes often involve multi-step processes that require careful optimization to achieve high yields and purity. However, advances in catalytic methods and green chemistry principles have provided new avenues for more efficient production. For instance, enzymatic approaches have been employed to introduce the hydroxymethyl and propionyl groups with high selectivity, reducing unwanted byproducts and improving overall sustainability.

In clinical settings, the potential applications of 4-(Hydroxymethyl)-3-propionylmandelic acid are still being explored through preclinical studies and pilot trials. Researchers are particularly interested in its ability to modulate inflammation by inhibiting key signaling pathways such as NF-κB and MAPK. Preliminary data suggest that certain derivatives may exhibit anti-inflammatory effects comparable to existing therapeutics but with improved pharmacokinetic profiles. Additionally, its antioxidant properties have been linked to potential neuroprotective effects, raising interest in its use for neurodegenerative diseases.

The future direction of research on 4-(Hydroxymethyl)-3-propionylmandelic acid is likely to focus on expanding its therapeutic applications through structural optimization and formulation development. By leveraging computational drug design tools, scientists aim to identify novel analogs with enhanced potency and reduced side effects. Furthermore, exploring its role in combination therapies may unlock new treatment strategies for complex diseases where single-agent approaches have limitations.

In conclusion, 4-(Hydroxymethyl)-3-propionylmandelic acid (CAS No. 1805908-27-3) represents a promising compound with diverse biological activities and synthetic utility. Its unique structural features make it a valuable scaffold for developing new pharmaceuticals targeting various diseases. As research continues to uncover its potential benefits, this compound is poised to play an increasingly important role in modern medicine.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)